RxDoctor Payments Data

Holly Starnes

Family · Raleigh, NCNPI 1104099761

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $44,229 of the $68,917 with a category attached, or 64.2%. AstraZeneca accounts for 88.9% of it on its own, with 50 other manufacturers making up the rest. 2025 is the largest year on record at $22,464, 7.1 times the $3,144 reported in 2021. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,917in general payments, 2019–2025

Across 586 payments — averaging $117.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$61K
  • AbbVie$2K
  • MDD US Operations, LLC$526
  • UCB, Inc.$389
  • Amgen$370
  • Novartis$340
  • plus $4K from 45 others

What the payments were for

  • Consulting fees$4501%
  • Speaking & faculty fees$44,22964%
  • Travel & lodging$12,46218%
  • Food & beverage$11,77617%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,917 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$48,400
Medicare patients
376
Services billed
999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe105$81,861
Emgality PenGalcanezumab-Gnlm69$54,466
UbrelvyUbrogepant34$41,406
Lamictal XrLamotrigine11$35,838
Nurtec OdtRimegepant Sulfate28$31,395
Ajovy AutoinjectorFremanezumab-Vfrm33$24,417
Carbamazepine ErCarbamazepine38$10,019
NamzaricMemantine Hcl/Donepezil Hcl13$7,523
Gabapentin378$6,617
Lamotrigine ErLamotrigine22$6,267
Memantine Hcl267$5,588
Depakote ErDivalproex Sodium12$5,020
Lacosamide52$4,757
Galantamine Hbr77$4,540
Primidone112$2,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Namzaric$1,977$48,93047 claims
PfizerNurtec Odt, Dilantin$151$32,53340 claims
Upsher-smith Laboratories LLCTopiramate$70$2,118148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →